Clinical trials: Ligneous Conjunctivitis
Ligneous Conjunctivitis, Left Eye
Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis
Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request from the Sponsor-Investigator…
- Trial name
- NCT04275232
- Testing
- Allogenic plasma aliquots, a source of plasminogen
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Dorothy Bautista, MD
Ligneous Conjunctivitis
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen…
- Trial name
- NCT04586062
- Testing
- Plasminogen
- Sponsor
- Kedrion S.p.A.
Ligneous Conjunctivitis
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
Kedrion Human Plasminogen, a sterile human plasma-derived plasminogen preparation for topical ocular use will be evaluated for the indication of treatment of ligneous conjunctivitis.
- Trial name
- NCT01554956
- Testing
- Human Plasminogen
- Where
- 3 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Kedrion S.p.A.
Plasminogen Deficiency
Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency
Congenital plasminogen deficiency causes impaired wound healing and growth of pseudomembranous lesions over multiple parts of the body. The most common lesions involve eyes and are known as Ligneous conjunctivitis.
- Trial name
- NCT05404932
- Testing
- Aliquoted allogeneic donor plasma in patient's conjunctiva
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Saskatchewan